Clinical trials: Growth Delay

Osteogenesis Imperfecta

Growth Hormone Therapy in Osteogenesis Imperfecta

• Completed
• Age: 3 to 16 years
• Phase 3
• Results posted

Growth deficiency is a key feature of severe Osteogenesis Imperfecta (OI) and a frequent feature of mild to moderate forms of the disease. The reason that children with OI are short is not fully understood.

Trial name

NCT00001305

Testing

Humatrope

Where

United States

Volunteers

42 people

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)